Alphamab Oncology announced that Mr. XU Zhan Kevin ("Mr. Xu") has tendered his resignation from the position as a non-executive Director with effect from June 30, 2023 due to his other work commitments. Following his resignation as a non-executive Director, Mr. Xu has ceased to be a member of the strategy committee of the Company.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 HKD | -2.28% | -11.13% | -29.07% |
05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.07% | 597M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee